Welcome to our dedicated page for Acumen Pharmaceuticals news (Ticker: ABOS), a resource for investors and traders seeking the latest updates and insights on Acumen Pharmaceuticals stock.
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) is a clinical-stage biopharmaceutical company whose news flow centers on the development of sabirnetug (ACU193), a humanized monoclonal antibody targeting toxic soluble amyloid beta oligomers (AβOs) for the treatment of early Alzheimer’s disease. Company updates consistently highlight progress in its Phase 2 ALTITUDE-AD trial, scientific presentations, collaborations and financial disclosures.
Visitors to this ABOS news page can review press releases on key clinical milestones, such as enrollment updates and the initiation of the open-label extension portion of ALTITUDE-AD, as well as data readouts from the Phase 1 INTERCEPT-AD study and subsequent analyses. Acumen also reports on operational innovations in trial execution, including the use of a plasma pTau217 assay to streamline screening and reduce costs in its Phase 2 program.
In addition to clinical trial developments, Acumen regularly announces scientific findings presented at major Alzheimer’s and neurology conferences. These items include data on sabirnetug’s selectivity for AβOs over monomeric amyloid beta, biomarker results, and research on Enhanced Brain Delivery (EBD™) approaches in collaboration with JCR Pharmaceuticals using transferrin-receptor-targeting, blood–brain barrier-penetrating technology.
Investors and followers of ABOS will also find news related to corporate events, such as board appointments, strategic collaboration agreements and quarterly financial results, which are often accompanied by conference call and webcast details. This page provides a centralized view of Acumen’s public communications as it advances its AβO-targeted therapeutic programs for Alzheimer’s disease.
Acumen Pharmaceuticals (NASDAQ: ABOS) announces publication in Frontiers in Neuroscience of preclinical evidence supporting ACU193, a monoclonal antibody targeting amyloid beta oligomers for early Alzheimer's disease treatment. The publication indicates that AβO-mediated neuronal toxicity contributes to cognitive impairments in Alzheimer's patients. Key findings include ACU193's selectivity towards AβOs without binding to plaques, suggesting a reduced risk of amyloid-related imaging abnormalities. Ongoing Phase I clinical trials aim to validate these findings and explore ACU193's therapeutic potential.
Acumen Pharmaceuticals (NASDAQ: ABOS) reported progress on ACU193, its monoclonal antibody targeting toxic amyloid-beta oligomers, currently in Phase 1 clinical trial INTERCEPT-AD for early Alzheimer's patients. The trial has experienced slower enrollment due to COVID-19, but topline results are expected in H1 2023. Acumen ended 2021 with $225.9 million in cash, sufficient to fund operations through 2025. The company's leadership was strengthened with new appointments, including Kim Drapkin to the Board. Net losses were $100.6 million in 2021, primarily due to non-cash expenses related to fair value changes.
Acumen Pharmaceuticals (ABOS) will report its financial results for Q4 and full year 2021 on March 28, 2022, at 4:30 PM ET. The company is focused on developing targeted therapeutics for Alzheimer’s disease, particularly its investigational drug ACU193, an immunotherapy targeting toxic AβOs, currently in a Phase I clinical trial. This conference call will update stakeholders on business and financial matters, with access available via the company’s website.
Acumen Pharmaceuticals, focusing on Alzheimer’s disease therapeutics, achieved a significant milestone by enrolling the first patients in the INTERCEPT-AD Phase 1 clinical trial for its investigational drug, ACU193. This humanized monoclonal antibody selectively targets toxic amyloid-beta oligomers (AβOs). Despite delays attributed to the COVID-19 Delta variant, Acumen expects to report topline data by the end of 2022. The company reported a net loss of $92.3 million for the nine-month period ending September 30, 2021, with cash and cash equivalents totaling $135.8 million.
Acumen Pharmaceuticals, a clinical stage biopharmaceutical company focused on Alzheimer's disease, announced participation in two upcoming virtual conferences. The first is the Credit Suisse 30th Annual Healthcare Conference on November 9, 2021, at 9:40 AM EST, followed by the Stifel 2021 Healthcare Conference on November 16, 2021, at 10:00 AM EST. Live webcasts will be accessible on-demand for 30 days after each event on their website. Acumen is advancing its investigational product ACU193, targeting toxic AβOs in early Alzheimer's patients.
Acumen Pharmaceuticals (NASDAQ: ABOS) announced its participation in the 2021 Clinical Trials on Alzheimer’s Disease (CTAD) conference, where it will present on its investigational drug ACU193. This monoclonal antibody targets toxic amyloid-beta oligomers, a key factor in Alzheimer’s disease pathology. The INTERCEPT-AD trial, currently enrolling early Alzheimer’s patients, aims to assess safety and cognitive improvements. The presentation is scheduled for November 10, 2021, and emphasizes ACU193's potential to modify disease progression with improved synaptic function.
Acumen Pharmaceuticals has initiated dosing in its Phase 1 clinical trial, INTERCEPT-AD, for ACU193, a monoclonal antibody targeting toxic amyloid-beta oligomers in early Alzheimer’s patients. This trial aims to establish safety, pharmacokinetics, and target engagement and will enroll approximately 62 participants. The CEO expressed optimism regarding ACU193's potential to meet unmet medical needs in Alzheimer’s treatment, highlighting its unique mechanism compared to other monoclonal antibodies.
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) reported Q2 2021 financial results, highlighting substantial progress in its clinical trial for ACU193, which targets toxic amyloid-beta oligomers linked to Alzheimer’s disease. The company closed an IPO in July 2021, raising approximately $168.6 million, boosting cash reserves to over $235 million. R&D expenses rose to $2.3 million for Q2 2021, while net losses surged to $61.4 million, largely due to non-cash expenses related to warrant liabilities. The ongoing Phase 1 trial, ACU-001, is expected to yield top-line results by the end of 2022.
Acumen Pharmaceuticals (Nasdaq: ABOS) has priced its upsized initial public offering (IPO) of 9,999,999 shares at $16.00 each, raising approximately $160 million before expenses. The offering will close on July 6, 2021, with shares expected to start trading on July 1, 2021. Acumen has granted underwriters a 30-day option for an additional 1,499,999 shares. The funds will support the development of ACU193, a therapy targeting Alzheimer’s disease. The company initiated a Phase 1 clinical trial for ACU193 in Q2 2021, with results expected by the end of 2022.